Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/119047
Full metadata record
DC FieldValueLanguage
dc.creatorSantos, S
dc.creatorJunqueira, M
dc.creatorFrancisco, G
dc.creatorVilanova, M
dc.creatorMagalhães, A
dc.creatorBaruffi, M
dc.creatorChammas, R
dc.creatorHarris, A
dc.creatorReis, CA
dc.creatorBernardes, E
dc.date.accessioned2019-02-21T12:16:25Z-
dc.date.available2019-02-21T12:16:25Z-
dc.date.issued2016
dc.identifier.issn1949-2553
dc.identifier.urihttps://hdl.handle.net/10216/119047-
dc.description.abstractST6GalNAc-I, the sialyltransferase responsible for sialyl-Tn (sTn) synthesis, has been previously reported to be positively associated with cancer aggressiveness. Here we describe a novel sTn-dependent mechanism for chemotherapeutic resistance. We show that sTn protects cancer cells against chemotherapeutic-induced cell death by decreasing the interaction of cell surface glycan receptors with galectin-3 and increasing its intracellular accumulation. Moreover, exogenously added galectin-3 potentiated the chemotherapeutics-induced cytotoxicity in sTn non-expressing cells, while sTn overexpressing cells were protected. We also found that the expression of sTn was associated with a reduction in galectin-3-binding sites in human gastric samples tumors. ST6GalNAc-I knockdown restored galectin-3-binding sites on the cell surface and chemotherapeutics sensibility. Our results clearly demonstrate that an interruption of O-glycans extension caused by ST6GalNAc-I enzymatic activity leads to tumor cells resistance to chemotherapeutic drugs, highlighting the need for the development of novel strategies to target galectin-3 and/or ST6GalNAc-I.
dc.description.sponsorshipThis work was supported by funding from the São Paulo Research Foundation (FAPESP grant number 2012/06875-6), the Coordination for the Improvement of Higher Education Personnel (CAPES). CR acknowledges IPATIMUP, which integrates the i3S Research Unit, which is partially supported by FCT, the Portuguese Foundation for Science and Technology. CR work is funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE and National Funds through the FCT, under the projects: PEst-C/SAU/ LA0003/2013, PTDC/BBB-EBI/0786/2012 PTDC/BBB-EBI/0567/2014 and GastricGlycoExplorer (grant number 316929). MDB acknowledges Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq, grant numbers 467646/2014-7]. Also, the research leading to these results has received support and funding from the Núcleo de Apoio à Pesquisa em Doenças Inflamatórias [NAPDIN, grant number 11.1.21625.01.0]. ALH acknowledges the Cancer Research UK and the Breast Cancer Research Foundation.
dc.language.isoeng
dc.publisherImpact Journals
dc.relationinfo:eu-repo/grantAgreement/FCT/COMPETE/132983/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/COMPETE/125428/PT
dc.relation.ispartofOncotarget, vol.7(50), p. 83570-83587
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/
dc.subjectAnimals
dc.subjectAntigens, Tumor-Associated, Carbohydrate/genetics
dc.subjectAntigens, Tumor-Associated, Carbohydrate/metabolism
dc.subjectAntineoplastic Agents/pharmacology
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectCisplatin/pharmacology
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Resistance, Neoplasm
dc.subjectGalectin 3/metabolism
dc.subjectGlycosylation
dc.subjectHumans
dc.subjectMice, Inbred BALB C
dc.subjectMice, Nude
dc.subjectProtein Processing, Post-Translational
dc.subjectProtein Transport
dc.subjectRNA Interference
dc.subjectSialyltransferases/genetics
dc.subjectSialyltransferases/metabolism
dc.subjectStomach Neoplasms/drug therapy
dc.subjectStomach Neoplasms/genetics
dc.subjectStomach Neoplasms/metabolism
dc.subjectStomach Neoplasms/pathology
dc.subjectTime Factors
dc.subjectTransfection
dc.subjectTumor Burden
dc.titleO-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.18632/oncotarget.13192
dc.relation.publisherversionhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13192&pubmed-linkout=1
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
Santos S et al., Oncotarget 2016.pdf2.28 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons